📊 HBIO Key Takeaways
Is HBIO a Good Investment? Thesis Analysis
Harvard Bioscience is experiencing severe financial distress with a $48.6M operating loss and $56.7M net loss despite solid 57.7% gross margins, indicating critical execution or operational structure failures. The company's 2.61x debt-to-equity ratio combined with negative interest coverage ratio (-13.5x) and declining revenue (-8.1% YoY) creates acute refinancing and solvency risk.
Why Buy HBIO? Key Strengths
- Gross margin of 57.7% demonstrates strong underlying product unit economics and pricing power
- Positive operating cash flow of $6.7M and free cash flow of $5.5M despite losses shows the business generates cash
- Current ratio of 2.20x indicates adequate short-term liquidity to meet immediate obligations
HBIO Investment Risks to Consider
- Massive operating loss of -$48.6M with -56.1% operating margin indicates severe cost structure misalignment or demand collapse
- Very high leverage with 2.61x debt-to-equity ratio and $35.9M long-term debt against only $13.7M stockholders equity creates refinancing risk
- Negative interest coverage ratio of -13.5x means operating income cannot cover interest payments, threatening debt service capability
- Revenue declining 8.1% YoY combined with worsening losses suggests structural business deterioration rather than cyclical downturn
- Stockholders equity of only $13.7M represents only 17% of total assets, leaving minimal buffer for further losses
Key Metrics to Watch
- Operating margin improvement trajectory (currently -56.1%) and return to profitability
- Revenue stabilization and growth resumption (currently declining)
- Debt refinancing activity and covenant compliance given negative interest coverage
- Operating expense reduction and restructuring progress
- Cash burn rate and runway relative to debt obligations
HBIO Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 2.20x current ratio provides a solid financial cushion.
HBIO Profitability Ratios
HBIO vs Default Sector
How HARVARD BIOSCIENCE INC compares to Default sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is HBIO Overvalued or Undervalued?
Based on fundamental analysis, HARVARD BIOSCIENCE INC shows some fundamental concerns relative to the Default sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
HBIO Balance Sheet & Liquidity
HBIO 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: HARVARD BIOSCIENCE INC's revenue has declined by 21% over the 5-year period, indicating business contraction. The most recent EPS of $-0.28 indicates the company is currently unprofitable.
HBIO Growth Metrics (YoY)
HBIO Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $20.6M | -$1.2M | $-0.03 |
| Q2 2025 | $20.5M | -$2.3M | $-0.05 |
| Q1 2025 | $21.8M | -$4.7M | $-0.11 |
| Q3 2024 | $22.0M | -$1.2M | $-0.03 |
| Q2 2024 | $23.1M | -$358.0K | $-0.01 |
| Q1 2024 | $24.5M | $622.0K | $0.01 |
| Q3 2023 | $25.4M | -$1.2M | $-0.03 |
| Q2 2023 | $28.8M | -$358.0K | $-0.01 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
HBIO Capital Allocation
HBIO SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for HARVARD BIOSCIENCE INC (CIK: 0001123494)
📋 Recent SEC Filings
❓ Frequently Asked Questions about HBIO
What is the AI rating for HBIO?
HARVARD BIOSCIENCE INC (HBIO) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are HBIO's key strengths?
Claude: Gross margin of 57.7% demonstrates strong underlying product unit economics and pricing power. Positive operating cash flow of $6.7M and free cash flow of $5.5M despite losses shows the business generates cash.
What are the risks of investing in HBIO?
Claude: Massive operating loss of -$48.6M with -56.1% operating margin indicates severe cost structure misalignment or demand collapse. Very high leverage with 2.61x debt-to-equity ratio and $35.9M long-term debt against only $13.7M stockholders equity creates refinancing risk.
What is HBIO's revenue and growth?
HARVARD BIOSCIENCE INC reported revenue of $86.6M.
Does HBIO pay dividends?
HARVARD BIOSCIENCE INC does not currently pay dividends.
Where can I find HBIO SEC filings?
Official SEC filings for HARVARD BIOSCIENCE INC (CIK: 0001123494) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is HBIO's EPS?
HARVARD BIOSCIENCE INC has a diluted EPS of $-1.28.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is HBIO a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, HARVARD BIOSCIENCE INC has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is HBIO stock overvalued or undervalued?
Valuation metrics for HBIO: ROE of -412.8% (sector avg: 15%), net margin of -65.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy HBIO stock in 2026?
Our dual AI analysis gives HARVARD BIOSCIENCE INC a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is HBIO's free cash flow?
HARVARD BIOSCIENCE INC's operating cash flow is $6.7M, with capital expenditures of $1.3M. FCF margin is 6.3%.
How does HBIO compare to other Default stocks?
Vs Default sector averages: Net margin -65.5% (avg: 12%), ROE -412.8% (avg: 15%), current ratio 2.20 (avg: 1.8).